BDD Press Releases
BDD’s OralogiK™ technology dosed in Parkinson’s patients for the first time. – Phase 1b trial of CP-012
BDD's OralogiK™ technology dosed in Parkinson's patients for…
Contera Pharma and BDD Pharma announce dosing of first subject in a Phase 1 trial of CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing…
BDD secures £2M to fuel expansion in early phase clinical trials following record year
BDD secures £2M to fuel expansion in early phase clinical trials…
BDD Pharma Ltd Unveils Updated Logo for 2023
Glasgow, Scotland, United Kingdom – BDD Pharma Ltd, a…
BDD Pharma signs agreement with Contera Pharma for development of a novel tablet formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
BDD Pharma signs agreement with Contera Pharma for development…
Claire Madden-Smith joins BDD Pharma Board as Non-Executive Director
BDD PHARMA LIMITED
For immediate release – June 13th 2022
Claire…
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders Using OralogiK™
May 24, 2022 Cingulate Announces Complete Enrollment in Human…
BDD Pharma Further Invests in Gamma Scintigraphy Capabilities
BDD Pharma, world leaders in gamma scintigraphic imaging have…
Investment to respond to growth in demand for integrated services at UK drug delivery company BDD
Dec 14, 2020 Investment to respond to growth in demand for integrated…
Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin
Feb 13, 2020 Innovation Pharmaceuticals Phase 1 Trial of Brilacidin…
BDD signs agreement with Innovation Pharmaceuticals for Advanced Oral Tablet Technology in Treating Inflammatory Bowel Disease
Jun 06, 2019 BDD signs agreement with Innovation Pharmaceuticals…
